SUBSCRIBE
SUBSCRIBE

Pain

FDA signage at its office in Maryland
FDA
Eyenovia, Formosa Win FDA Approval for Anti-Inflammatory Eye Drops
The regulator has approved Eyenovia and Formosa’s ophthalmic clobetasol propionate solution to ease eye inflammation and pain after surgery, with a potential $1.3 billion market.
March 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Falling Pain Pill Bottles / Taylor Tiede
Latigo Launches into Non-Opioid Pain Medicine Space with $135 Million Series A
Two weeks after Vertex’s Phase III data for VX-548 reenergized the field, Latigo Biotherapeutics announced $135 million in Series A funds to push its own NaV1.8 inhibitor into Phase II.
February 13, 2024
 · 
3 min read
 · 
Heather McKenzie
Load More
PRESS RELEASES
Press Releases
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
March 12, 2025
 · 
5 min read
Press Releases
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
March 5, 2025
 · 
4 min read
Press Releases
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
March 5, 2025
 · 
6 min read
Press Releases
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
March 4, 2025
 · 
3 min read
Press Releases
Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain
March 4, 2025
 · 
3 min read
Press Releases
SynerFuse™ Proof-of-Concept Study Completed
March 4, 2025
 · 
8 min read
Press Releases
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
March 3, 2025
 · 
3 min read
Press Releases
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
February 26, 2025
 · 
6 min read
Press Releases
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
February 25, 2025
 · 
4 min read
Press Releases
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
February 21, 2025
 · 
1 min read
Press Releases
Epidural Steroid Injections for Chronic Back Pain: An AAN Systematic Review
February 19, 2025
 · 
3 min read
Press Releases
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
February 14, 2025
 · 
3 min read
Press Releases
Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook
February 13, 2025
 · 
5 min read
Press Releases
Navega Therapeutics Announces CIRM Grant for Treatment of Chronic Pain
February 5, 2025
 · 
3 min read
Press Releases
Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain
February 4, 2025
 · 
3 min read
Press Releases
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
January 30, 2025
 · 
3 min read
Press Releases
OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment
January 30, 2025
 · 
3 min read
Press Releases
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch
January 14, 2025
 · 
8 min read
Press Releases
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
January 13, 2025
 · 
14 min read
Press Releases
KitoTech Medical Introduces PainPause, a Consumer Product That Provides A Safe and Effective New Approach to Treating Pain
January 8, 2025
 · 
2 min read
Load More